MICA/B Expression in Pancreatic Cancer and the Role of Uric Acid
Author Information
Author(s): Xu Xiulong, Rao Geetha S, Groh Veronika, Spies Thomas, Gattuso Paolo, Kaufman Howard L, Plate Janet, Prinz Richard A
Primary Institution: Rush University Medical Center
Hypothesis
Can gemcitabine affect MICA/B expression and natural killer cytotoxicity in pancreatic cancer?
Conclusion
MICA/B expression is elevated in pancreatic cancer tissues and serum, and is influenced by uric acid production during DNA damage.
Supporting Evidence
- 68% of pancreatic ductal adenocarcinomas showed positive MICA/B expression.
- Serum MICA levels were significantly higher in pancreatic cancer patients compared to healthy controls.
- Gemcitabine treatment increased serum MICA levels in 6 out of 10 patients.
Takeaway
This study found that a protein called MICA/B is higher in people with pancreatic cancer, and that a drug called gemcitabine can increase its levels.
Methodology
The study analyzed MICA/B expression in pancreatic cancer cell lines and patient samples using flow cytometry, immunohistochemistry, and ELISA.
Limitations
The study did not find a correlation between serum MICA levels and patient survival.
Participant Demographics
61 patients with pancreatic ductal adenocarcinoma, 15 male and 10 female, mean age 65.
Statistical Information
P-Value
0.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website